Investors Encouraged to Join Class Action Against Vistagen Therapeutics Over Securities Fraud Allegations

In a significant move within the investment community, the Schall Law Firm, a renowned national litigation firm for shareholder rights, is urging investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) to take action following a class action lawsuit. This legal action addresses serious allegations pertaining to securities fraud, specifically violations of the Securities Exchange Act of 1934.

The class action concerns incidents between April 1, 2024, and December 16, 2025, during which time investors purchased Vistagen's securities. In a public announcement made on March 2, 2026, the law firm highlighted the urgency for affected investors to reach out before the March 16th deadline to secure their participation in the lawsuit.

Background and Allegations

The allegations center on claims that Vistagen presented false and misleading information to the market, specifically regarding its drug candidate, fasedienol. Vistagen purportedly gave investors an unwarranted sense of security regarding the success of its Phase 3 PALISADE-2 trial, suggesting positive results that were not substantiated by factual evidence. Moreover, the company allegedly minimized the risks associated with potential failures in clinical studies, leading to detrimental impacts on investors once the truth surfaced.

As stated in the lawsuit, the company’s public communications were not only misrepresentative, but also materially misleading throughout the designated class period. As a result, when the realities of Vistagen’s performance came to light, numerous investors experienced significant financial losses.

Importance of Taking Action

For investors who believe they were negatively impacted by these misleading statements, this class action represents an opportunity to seek restitution for their losses. The Schall Law Firm, known for its specialization in securities-related legal battles, is handling the case and encourages all affected shareholders to step forward. Potential claimants can contact Brian Schall directly at the firm's office in Los Angeles or visit their website for additional information.

It is essential for affected investors to understand that they are not yet officially represented until the class action is certified. Thus, taking proactive steps is crucial to ensure their rights are protected as proceedings develop.

Call to Action

If you are a shareholder who suffered losses attributed to the mismanagement and misinformation of Vistagen Therapeutics, you are strongly encouraged to engage with the Schall Law Firm. The legal team is prepared to provide consultations at no charge and guide you through the process of participating in this crucial lawsuit.

As the scenario unfolds, the Schall Law Firm will continue to keep investors informed about the lawsuit's progress and what it means for shareholders. The firm emphasizes that this is a moment for investors to unite and hold the company accountable, ensuring that their voices and grievances are formally heard in the courthouse.

In conclusion, the ongoing case against Vistagen Therapeutics highlights the complexities and risks associated with investment in pharmaceutical companies, especially those navigating clinical trials and regulatory landscapes. With the support of a reputable firm like Schall Law, investors have a pathway to reclaiming their losses and contributing to transparency within the industry.

For more information on how to participate in the class action lawsuit against Vistagen Therapeutics, you can reach the Schall Law Firm at the following contact details:

- Contact: Brian Schall, Esq.
- Phone: 310-301-3335
- Website: www.schallfirm.com

Take action before it's too late, and ensure your rights as an investor are upheld.